Results 221 to 230 of about 1,745,820 (365)

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

LEGAL STATUS OF PATENT ATTORNEYS, TRADE MARK ATTORNEYS UNDER THE UNITED KINGDOM LAW

, 2017
Khrystyna Kmetyk
openalex   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

Vivianite and Its Oxidation Products in Mammoth Ivory and Their Implications to the Burial Process

ACS Omega, 2021
Mengmeng Shen, Zhiyun Lu, Yan Xu, Xuemei He   +3 more
doaj   +1 more source

Evaluation of tubal patency with hysterosalpingo-contrast sonography using sodium alginate solution and the subsequent fertility outcomes in repeat breeder cattle. [PDF]

J Reprod Dev
Ito K, Hashimoto R, Endo N, Tanaka T.
europepmc   +1 more source

Radiocephalic Arteriovenous Fistula Patency and Use

, 2022
Patrick Heindel, Peng Yu, Jessica D. Feliz, Dirk M. Hentschel, Steven K. Burke, Mohammed Al‐Omran, Deepak L. Bhatt, Michael Belkin, C. Keith Ozaki, Mohamad A. Hussain   +9 more
openalex   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

Massive drainage from incision after tunica vaginalis eversion: A case of patent processus vaginalis. [PDF]

Urol Case Rep
Bao W, Hu X, Ma X, Liu YY, Duan J, Huang R.   +5 more
europepmc   +1 more source

Research, Patent, and Industrialization in Nanoimprint Technology

, 2008
Yoshihiro Todokoro
openalex   +2 more sources

The Use and Misuse of Patent Data: Issues for Corporate Finance and Beyond

, 2017
J. Lerner, Amit Seru
semanticscholar   +1 more source